Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
480 Mometasone Furoate Sinus Drug Depot · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 480 Mometasone Furoate Sinus Drug Depot | EXPERIMENTAL | 480 Mometasone Furoate Sinus Drug Depot |
| Name | Type | Description |
|---|---|---|
| 480 Mometasone Furoate Sinus Drug Depot | DRUG | Management of Chronic Sinusitis |
Inclusion Criteria: * Diagnosis of CS. * Female study subjects of child-bearing potential must have a negative pregnancy test and must agree to not become pregnant during the course of the study. * The study subject has been informed of the nature of the study, agrees to its provisions and has prov...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE3 | Itepekimab |
| AstraZeneca PLC | AZN | 4 | PHASE3 | Tezepelumab |
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150, Standard therapy for INCS |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | - | Undisclosed |
480 Mometasone Furoate Sinus Drug Depot is an investigational small molecule being developed for chronic sinusitis. It is designed to deliver mometasone furoate directly to the sinus cavity. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
480 Mometasone Furoate Sinus Drug Depot is being developed by Lyra Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol LYRA. The company is focused on developing innovative therapies for ear, nose, and throat (ENT) conditions.
480 Mometasone Furoate Sinus Drug Depot is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or any other regulatory agency. The drug is being studied for the treatment of chronic sinusitis.
480 Mometasone Furoate Sinus Drug Depot has been studied in one completed Phase 1 clinical trial, identified as NCT02967731. This trial, titled '480 Biomedical Sinus Drug Depot,' enrolled 20 participants with chronic sinusitis in Australia and New Zealand. The trial was uncontrolled and not randomized or double-blinded.
480 Mometasone Furoate Sinus Drug Depot is a small molecule that contains mometasone furoate, a corticosteroid. It is designed to be placed in the sinus cavity to deliver the medication locally. The drug targets inflammation in the sinuses, which is a key factor in chronic sinusitis.